Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0WU9R
|
|||
| Former ID |
DNC004182
|
|||
| Drug Name |
L-741742
|
|||
| Synonyms |
L-741742; UNII-C5B89UM05U; CHEMBL444309; C5B89UM05U; L 741742; L-741,742; L741742; Cmpepi-3; Tocris-1004; Biomol-NT_000048; GTPL3302; SCHEMBL1388774; BPBio1_001096; DTXSID0043894; CHEBI:92229; ZINC602172; AC1L3203; BDBM50050476; NCGC00024933-02; NCGC00024933-01; L016523; L 741,742; BRD-K13211965-001-02-2; BRD-K13211965-003-01-0; BRD-K13211965-001-01-4; 5-(4-chlorophenyl)-4-methyl-3-(1-phenethylpiperidin-4-yl)-1,2-oxazole; 5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H25ClN2O
|
|||
| Canonical SMILES |
CC1=C(ON=C1C2CCN(CC2)CCC3=CC=CC=C3)C4=CC=C(C=C4)Cl
|
|||
| InChI |
1S/C23H25ClN2O/c1-17-22(25-27-23(17)20-7-9-21(24)10-8-20)19-12-15-26(16-13-19)14-11-18-5-3-2-4-6-18/h2-10,19H,11-16H2,1H3
|
|||
| InChIKey |
QDMAKDIDFJTXEL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 156337-32-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:92229
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dopamine D3 receptor (D3R) | Target Info | Inhibitor | [2] |
| Dopamine D4 receptor (D4R) | Target Info | Inhibitor | [2] | |
| Sodium channel unspecific (NaC) | Target Info | Inhibitor | [3] | |
| Voltage-gated sodium channel alpha Nav1.3 (SCN3A) | Target Info | Inhibitor | [3] | |
| KEGG Pathway | Dopaminergic synapse | |||
| Neuroactive ligand-receptor interaction | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Dopamine receptor mediated signaling pathway | ||||
| Nicotine pharmacodynamics pathway | ||||
| Reactome | Interaction between L1 and Ankyrins | |||
| Dopamine receptors | ||||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Nicotine Activity on Dopaminergic Neurons | ||||
| GPCRs, Other | ||||
| Hypothetical Network for Drug Addiction | ||||
| Genes and (Common) Pathways Underlying Drug Addiction | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3302). | |||
| REF 2 | 5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: a potent, selective antagonist at human cloned dopamine D4 receptors. J Med Chem. 1996 May 10;39(10):1943-5. | |||
| REF 3 | 1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1, 3-dihydroimidazol-2-one: a selective high-affinity antagonist for the human dopamine D(4) rece... J Med Chem. 1999 Jul 15;42(14):2706-15. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.